KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) EPS (Weighted Average and Diluted) (2019 - 2025)

Alnylam Pharmaceuticals' EPS (Weighted Average and Diluted) history spans 7 years, with the latest figure at $0.82 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 226.15% year-over-year to $0.82; the TTM value through Dec 2025 reached $2.01, up 192.63%, while the annual FY2025 figure was $2.33, 206.88% up from the prior year.
  • EPS (Weighted Average and Diluted) reached $0.82 in Q4 2025 per ALNY's latest filing, down from $1.84 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1.84 in Q3 2025 to a low of -$3.32 in Q3 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$1.01, with a median of -$1.24 recorded in 2023.
  • The largest YoY upside for EPS (Weighted Average and Diluted) was 311.49% in 2025 against a maximum downside of 292.31% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$2.16 in 2021, then rose by 22.22% to -$1.68 in 2022, then surged by 35.12% to -$1.09 in 2023, then soared by 40.37% to -$0.65 in 2024, then skyrocketed by 226.15% to $0.82 in 2025.
  • Per Business Quant, the three most recent readings for ALNY's EPS (Weighted Average and Diluted) are $0.82 (Q4 2025), $1.84 (Q3 2025), and -$0.51 (Q2 2025).